Locations:

An Ultrasonically Realistic 3D-Printed Model of the Superficial Femoral Artery

Promises a low-cost way to visualize areas of stenosis

A 3D-printed model of an atherosclerotic superficial femoral artery (SFA) can be used to provide realistic-appearing ultrasound characteristics at very low cost. So concludes a recent study by Paul Bishop, MSEE, RVT, and his colleagues in Cleveland Clinic’s Department of Vascular Surgery and Department of Biomedical Engineering.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Using commercially available 3D printing materials and equipment, the researchers created a 3D model of an atherosclerotic SFA based on actual geometry derived from a CT scan reconstructed and segmented using semi-automated methods and commercial software. Multiple 3D print materials were selected to simulate normal artery wall tissue and atherosclerotic plaque. When the researchers evaluated the 3D-printed model with ultrasound, they demonstrated that lumen geometry of the SFA model was similar to the geometry of the actual artery. Ultrasound was able to discern between the 3D-printed materials and to visualize regions with stenosis, as shown in the sample images below.

Stenosis in a 3D-printed superficial femoral artery model (left) is matched with its corresponding appearance on ultrasound (right).

Imaging replication was not perfect, however: Ultrasound measures of echogenicity and wave velocity were noted to differ between the model and biological tissue.

“Although the 3D-printed model didn’t demonstrate fully accurate ultrasound characteristics, it provided realistic imaging on our first attempt to create an ultrasound phantom using only commercially available equipment and materials,” says Bishop, Director of Cleveland Clinic’s Vascular Core Laboratory. “Visualization of the SFA model wall was enabled much as would be the case with an in vivo SFA despite differences in ultrasound properties from actual tissue.”

While noting that further research is needed to refine 3D printing materials to better replicate biological tissue, Bishop and colleagues say their model may be useful in cost-sensitive applications in which exact ultrasound accuracy is not necessary. Indeed, they estimate their total 3D printing material cost for the model to be under $20.

Advertisement

Their study was awarded the D.E. Strandness, MD, Scientific Award for Excellence in Scientific Research from the Society for Vascular Ultrasound in 2017 and has been submitted for publication.

Contact Bishop at bishopp@ccf.org.

Advertisement

Related Articles

scan of a blood vessel with white pointing arrow

Myocardial Bridges: Tailoring Care From Simple to Complex Cases

For severe cases, complete unroofing of the bridge is imperative

Black-and-white scan with red and blue highlights

Revising Carotid Duplex Criteria Helped Identify More Treatable Asymptomatic Stenosis

Lower threshold expanded revascularization candidacy without raising early complication rates

human intestines with inset showing gut microbes

TMAO Emerges as a Biomarker for AAA Risk

Elevated levels of the gut microbial metabolite predict prevalence and adverse outcomes in community-based study

physician pointing to a heart model and speaking to a woman

Cardiovascular Implications of Clonal Hematopoiesis of Indeterminate Potential (CHIP)

They generally depend on the mutated gene, clone size and clinical setting

cardiac echo and cardiac CT images side by side

Indexed CTA Measures Sharpen Risk Prediction in Ascending Aortopathy

Large analysis adds to evidence that absolute diameter alone may miss vulnerable patients

operating room during robotic lung transplant surgery

Successful First Case Launches Cleveland Clinic’s Robotic Lung Transplant Program

Procedure places the center among only a handful worldwide to offer the minimally invasive approach

stylized illustration of cholesterol particle floating in bloodstream

Novel siRNA Produces Deep, Durable Reduction in Lp(a)

Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability

converging lines on a graph pointing downward

Oxidized Phospholipids Track Closely With Lp(a) Reductions in Clinical Trial

Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran

Ad